作者: Tao Tom Du , Chang Lee
DOI:
关键词:
摘要: The present invention relates to a pharmaceutical formulation powder that contains 17α-hydroxyprogesterone caproate (17-OHPC) and the method of producing produces particles are suitable as an inhalant. formulations, methods kits powdered 17-OHPC taught herein may be used reduce cytokine interleukin-17 (IL-17 or IL-17A) levels in both broncheoalveolar lavage fluid (BALF) blood/serum involve inhibition p38 mitogen activating protein kinase (MAPK) activity. treat IL-17 and/or MAPK mediated auto-immune auto-inflammatory diseases. Such diseases include glucocorticoid (GC) insensitive related conditions. In alternate embodiment, combined use budesonide (BUD) fluticasone with 17-OPHC.